Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…CertaraFebruary 13, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence Blog Pediatric Drug Development: From “Wild West” to Model-Informed Confidence Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…CertaraFebruary 11, 2026
Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions Blog Delivering on Deadline: Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…CertaraDecember 29, 2025
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Publication Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…CertaraNovember 12, 2025
Supporting KalVista’s NDA Submission for a Novel HAE Treatment Case Study Supporting KalVista’s NDA Submission for a Novel HAE Treatment To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…Danielle PillsburyNovember 12, 2025
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Case Study Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…CertaraNovember 10, 2025
Key Lessons & Opportunities in applying NCA and PopPK to ADCs Blog Key Lessons & Opportunities in applying NCA and PopPK to ADCs Applying NCA and PopPK to ADCs helps decode complex PK, balance DAR effects, and guide…CertaraOctober 24, 2025
Essentials of Model-informed Drug Development in Oncology Blog Essentials of Model-informed Drug Development in Oncology Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…CertaraOctober 6, 2025
Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar] On-Demand Webinar Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar] Senior Director, Pharmacometric Software, Certara Keith has more than 20 years of global drug development…CertaraApril 24, 2025